Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Management

Management

2016040-19-Web

Fred Eshelman
CEO

Fred Eshelman is Chairman of The Medicines Company (MDCO), and is the founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests. After PPD he served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines. Furiex was sold to Forest Labs/Actavis in July, 2014. His career has also included positions as senior vice president (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Eshelman has served on the executive committee of the Medical Foundation of North Carolina was appointed by the NC General Assembly to serve on the Board of Governors for the state’s multi campus university system (Chair of Audit Committee) as well as the NC Biotechnology Center. In addition he chairs the board of visitors for the School of Pharmacy at UNC-CH. One of the top pharmacy programs in the United States, in May 2008 the school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession. Recently US News and World Report named the school Number 1 in the US.

He has received many awards including the Davie and Distinguished Service Awards from UNC, Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the NC Business Hall of Fame. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital and a BS in pharmacy from UNC-CH. He is a graduate of the OPM program at Harvard Business School.

innocrin-cmo-edwina-baskin-bey

Edwina Baskin-Bey, M.D.
Chief Medical Officer

Dr. Edwina Baskin-Bey leads the seviteronel clinical development programs. Dr. Baskin-Bey has strong experience with oncology drug development, in particular hormonal therapies for the treatment of prostate cancer. Immediately prior to joining Innocrin, Dr. Baskin-Bey served as Global Director of Oncology Development at Janssen where she led several prostate cancer development programs. Prior to Janssen, Dr. Baskin-Bey was Global Director of Oncology Development at Astellas Pharma in both Europe and the U.S., where she had responsibility for the development of six (Phase 0-4) oncology products, enzalutamide in particular.  Dr. Baskin–Bey was trained as a general surgeon at the Mayo Clinic, where she performed both basic science and clinical research through the National Institutes of Health. She received a Doctorate in Medicine from Mount Sinai/NYU and a double-major BA in Biology and Organic Chemistry from Hunter College.

innocrin-cfo-charles-osbourne

Charles F. Osborne, Jr. CPA 
Chief Financial Officer and Corporate Secretary

Mr. Osborne has more than 20 years of life sciences experience, including 16 years as the Chief Financial Officer of publicly-traded or venture-backed companies. Mr. Osborne joins Innocrin following 12 years as the Chief Financial Officer at SCYNEXIS, where he led the initial public and a follow-on offering on NASDAQ. Prior experience includes NOBEX, where he raised more than $60 million of venture capital, and International Murex Technologies Co., where he ran the world-wide finance group and assisted in the sale to Abbott Laboratories. Mr. Osborne holds a B.S. in Accounting from the University of North Carolina at Chapel Hill.